Inspire Investing LLC Has $396,000 Holdings in Pacira BioSciences, Inc. $PCRX

Inspire Investing LLC boosted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,556 shares of the company’s stock after purchasing an additional 2,868 shares during the quarter. Inspire Investing LLC’s holdings in Pacira BioSciences were worth $396,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. US Bancorp DE raised its stake in Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after purchasing an additional 537 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Pacira BioSciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after purchasing an additional 1,165 shares in the last quarter. Brooklyn Investment Group raised its stake in Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock valued at $56,000 after purchasing an additional 1,764 shares in the last quarter. GAMMA Investing LLC raised its stake in Pacira BioSciences by 112.8% during the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock worth $92,000 after acquiring an additional 1,958 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Pacira BioSciences by 7.7% during the second quarter. State of Alaska Department of Revenue now owns 27,561 shares of the company’s stock worth $658,000 after acquiring an additional 1,977 shares in the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insider Buying and Selling at Pacira BioSciences

In related news, Director Marcelo Bigal sold 4,912 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director directly owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on PCRX. Truist Financial raised Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Friday, July 25th. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Pacira BioSciences in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and an average price target of $33.40.

Pacira BioSciences Stock Performance

NASDAQ:PCRX opened at $22.26 on Tuesday. The stock has a market cap of $1.00 billion, a P/E ratio of -8.01 and a beta of 0.40. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average is $25.42 and its 200-day moving average is $24.82. Pacira BioSciences, Inc. has a 1-year low of $15.92 and a 1-year high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.01. The company had revenue of $181.10 million for the quarter, compared to analysts’ expectations of $183.11 million. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.96 earnings per share. Pacira BioSciences has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current year.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.